Burden of illness for super-refractory status epilepticus patients

被引:23
|
作者
Beg, Jamil M. [1 ]
Anderson, Thomas D. [1 ]
Francis, Kevin [2 ]
Meckley, Lisa M. [2 ]
Fitzhenry, David [2 ]
Foster, Todd [2 ]
Sukhtankar, Susheel [2 ]
Kanes, Stephen J. [1 ]
Moura, Lidia M. V. R. [3 ]
机构
[1] Sage Therapeut Inc, 215 First St, Cambridge, MA 02142 USA
[2] Trinity Partners, Waltham, MA USA
[3] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
关键词
Epilepsy; Super-refractory status epilepticus; Cost; Resource utilization; Burden of illness; Hospitalization; CONVULSIVE STATUS EPILEPTICUS; ADMINISTRATIVE DATA; CASE-DEFINITION; ICD CODES; EPILEPSY; VALIDATION; MORTALITY; RECOMMENDATIONS; PREVALENCE; PREDICTORS;
D O I
10.1080/13696998.2016.1223680
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: To provide an estimate of the annual number of super-refractory status epilepticus (SRSE) cases in the US and to evaluate utilization of hospital resources by these patients. Methods: The Premier Hospital Database was utilized to estimate the number of SRSE cases based on hospital discharges during 2012. Discharges were classified as SRSE cases based on an algorithm using seizure-related International Classification of Diseases-9 (ICD-9) codes, Intensive Care Unit (ICU) length of stay (LOS), and treatment protocols (e.g. benzodiazepines, anti-epileptic drugs (AEDs), and ventilator use). Secondary analyses were conducted using more restrictive algorithms for SRSE. Results: A total of 6,325 hospital discharges were classified as SRSE cases from a total of 5,300,000 hospital discharges. Applying a weighting based on hospital characteristics and 2012US demographics, this projected to an estimated 41,156 cases of SRSE in the US during 2012, an estimated incidence rate of similar to 13/100,000 annually for SRSE in the US. Secondary analyses using stricter SRSE algorithms resulted in estimated incidence rates of similar to 11/100,000 and 8/100,000 annually. The mean LOS for SRSE hospitalizations was 16.5 days (median =11; interquartile range [IQR]=6-20), and the mean ICU LOS was 9.3 days (median =6; IQR =3-12). The mean cost of an SRSE hospitalization was $51,247 (median = $33,294; 95% CI = $49,634-$52,861). Limitations: The analysis uses ICD-9 diagnostic codes and claims information, and there are inherent limitations in any methodology based on treatment protocol, which created challenges in distinguishing with complete accuracy between SRSE, RSE, and SE on the basis of care patterns in the database. Conclusion: SRSE is associated with high mortality and morbidity, which place a high burden on healthcare resources. Projections based upon the findings of this study suggest an estimated 25,821-41,959 cases of SRSE may occur in the US each year, but more in-depth studies are required.
引用
收藏
页码:45 / 53
页数:9
相关论文
共 50 条
  • [31] Factors associated with mortality in patients with super-refractory status epilepticus
    Yi-Ting Fang
    Tsung-Lin Lee
    Yi-Hsien Tu
    Sheng-Hsiang Lin
    Miao-Er Chien
    Chin-Wei Huang
    Kuei-Sen Hsu
    Yi-Jen Wu
    Scientific Reports, 12
  • [32] Treatment of Super-Refractory Status Epilepticus: A Review
    Ochoa, Juan G.
    Dougherty, Michelle
    Papanastassiou, Alex
    Gidal, Barry
    Mohamed, Ismail
    Vossler, David G.
    EPILEPSY CURRENTS, 2021, 21 (06) : 405 - 415
  • [33] Super-refractory status epilepticus in West China
    Tian, L.
    Li, Y.
    Xue, X.
    Wu, M.
    Liu, F.
    Hao, X.
    Zhou, D.
    ACTA NEUROLOGICA SCANDINAVICA, 2015, 132 (01): : 1 - 6
  • [34] Ketamine to treat super-refractory status epilepticus
    Alkhachroum, Ayham
    Der-Nigoghossian, Caroline A.
    Mathews, Elizabeth
    Massad, Nina
    Letchinger, Riva
    Doyle, Kevin
    Chiu, Wei-Ting
    Kromm, Julie
    Rubinos, Clio
    Velazquez, Angela
    Roh, David
    Agarwal, Sachin
    Park, Soojin
    Connolly, E. Sander
    Claassen, Jan
    NEUROLOGY, 2020, 95 (16) : E2286 - E2294
  • [35] The Roles of Glutamate Receptors and Their Antagonists in Status Epilepticus, Refractory Status Epilepticus, and Super-Refractory Status Epilepticus
    Huang, Tzu-Hsin
    Lai, Ming-Chi
    Chen, Yu-Shiue
    Huang, Chin-Wei
    BIOMEDICINES, 2023, 11 (03)
  • [36] Isoflurane treatment for refractory and super-refractory status epilepticus in dogs
    Sarpekidou, Eirini
    Polyzois, Georgios
    Papageorgiou, Virginia
    Savvas, Ioannis
    Polizopoulou, Zoe
    Kazakos, George
    FRONTIERS IN VETERINARY SCIENCE, 2024, 11
  • [37] Refractory and Super-Refractory Status Epilepticus Therapeutic Options and Prognosis
    Rossetti, Andrea O.
    NEUROLOGIC CLINICS, 2025, 43 (01) : 15 - 30
  • [38] A GLOBAL AUDIT OF TREATMENT OF REFRACTORY AND SUPER-REFRACTORY STATUS EPILEPTICUS
    Ferlisi, M.
    Hocker, S.
    Grade, M.
    Trinka, E.
    Shorvon, S.
    EPILEPSIA, 2014, 55 : 38 - 38
  • [39] The risk of hypoglycemia and the ketogenic diet for super-refractory status epilepticus patients
    Brozova, Klara
    Broz, Jan
    BRAIN & DEVELOPMENT, 2019, 41 (08): : 740 - 740
  • [40] Consensus Protocol the Treatment of super-Refractory Status Epilepticus
    Gomes, Daniel
    Pimentel, Jose
    Bentes, Carla
    Aguiar De Sousa, Diana
    Antunes, Ana Patricia
    Alvarez, Antonio
    Costa e Silva, Zelia
    ACTA MEDICA PORTUGUESA, 2018, 31 (10): : 598 - 605